Chinese scientists develop new vaccine for post-surgical cancer therapy
BEIJING - Chinese scientists have developed a tumor vaccine that can effectively inhibit the recurrence and metastasis of post-surgical cancer.
Surgical resection is one of the main clinical treatments of cancer. However, residual micro-tumor tissue or circulating tumor cells can cause tumor recurrence or metastasis, which is a major challenge in tumor treatment.
Scientists from Shanghai Institute of Materia Medica developed a personalized cancer vaccine that can induce patient-specific anti-tumor immunity response to prevent tumor recurrence and metastasis after surgical resection.
The vaccine has proven effective in experiments on mice and the research was published on Nature Communications on April 18.
The vaccine model might provide novel insights for post-surgical cancer immunotherapy, according to the research team.
- Chinese scientists develop nanozymes to target tumor cells
- No tariffs on anti-cancer medicines to China from May
- China joins hands with Japan, South Korea for cancer control
- Chinese scientists develop new technology to assist cancer surgery
- Chinese scientists develop novel hydrogel for post-surgical cancer treatment
- Human activity on Qinghai-Tibet Plateau dates back 100,000 years
- China launches scientific-computing agent for supercomputing network
- Investigation launched after abnormal death of infant in Hefei
- Fujian high court retries father in girl's torture death
- China builds integrated, intelligent monitoring network to safeguard biodiversity
- China sees marked rise in 5-year survival rate for pediatric, adolescent cancers
